Two recent reviews have been published in Oncology describing the history, developmental clinical study results, treatment optimization and future directions for radium-223 chloride in prostate and other cancers. It should be noted that these articles are primarily written for physicians and health care providers. See the accompanying links.
Radium-223 chloride (alpha-radin) is an alpha-particle- emitting radiopharmaceutical which is specifically taken up by bone cells (osteoblasts). These high energy alpha particles with short tissue penetration range allow for targeted prostate cancer cell killing with low toxicity. Improvement in overall survival and relief of skeletal symptoms have been demonstrated in prostate cancer patients who are hormone resistant and have multi-focal symptomatic bone metastases.